MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Non-motor symptoms burden grading in Parkinson disease with the Movement Disorders Society – Non-Motor Rating Scale (MDS-NMS)

D. Weintraub, C. Rodriguez-Blazquez, A. Schrag, A. Rizos, KR. Chaudhuri, P. Martinez-Martin (Madrid, Spain)

Meeting: 2019 International Congress

Abstract Number: 1645

Keywords: Non-motor Scales, Parkinsonism

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Motor Symptoms

Session Time: 1:15pm-2:45pm

Location: Agora 3 West, Level 3

Objective: To identify cut-off points on the Movement Disorders Society – Non Motor Rating Scale (MDS-NMS) for non-motor symptoms (NMS) burden grading.

Background: NMS burden increases as Parkinson disease (PD) progresses. A grading system for NMS burden using the recently developed MDS-NMS would allow for a complete and comprehensive PD patient classification when combined with the classical staging system based on motor manifestations.

Method: Data came from the multicenter, cross-sectional MDS-NMS validation study. PD patients from movement disorders clinics in United States and United Kingdom were assessed with the Hoehn & Yahr (HY) staging, the original Non-Motor Symptoms Scale (NMSS) and the new MDS-NMS. MDS-NMS mean total scores by HY stages and NMSS burden levels were calculated. Cut-off values for the MDS-NMS total score was determined using receiver operating characteristic (ROC) curve analysis, with NMSS burden levels as reference.

Results: The sample was composed by 402 PD patients, 62.2% men, that had mean age of 67.42 years old (standard deviation, SD: 9.96), mean PD duration of 8.2 years (SD: 5.93). HY stages distribution was: 51 (12.7%) patients in HY1; 219 (54.5%) in HY2; 111 (27.6%) in HY3 and 21 (5.2%) in HY4. Mean MDS-NMS total score increased with increasing HY stages (p<0.001). Using ROC curve, the following ranges of MDS-NMS burden levels were ascertained: mild, 1-44 points; moderate, 45-78; severe, 79-112; very severe, ≥113. The distribution of patients between the MDS-NMS burden levels were: mild, 141 (37.8%) patients; moderate, 90 (24.1%); severe, 51 (13.7%); and very severe, 90 (24.1%).

Conclusion: Cut-off values for categorizing PD patients based on their NMS burden using the MDS-NMS are proposed. These burden levels can complement the existing PD patients staging systems based on motor symptoms.

To cite this abstract in AMA style:

D. Weintraub, C. Rodriguez-Blazquez, A. Schrag, A. Rizos, KR. Chaudhuri, P. Martinez-Martin. Non-motor symptoms burden grading in Parkinson disease with the Movement Disorders Society – Non-Motor Rating Scale (MDS-NMS) [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/non-motor-symptoms-burden-grading-in-parkinson-disease-with-the-movement-disorders-society-non-motor-rating-scale-mds-nms/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/non-motor-symptoms-burden-grading-in-parkinson-disease-with-the-movement-disorders-society-non-motor-rating-scale-mds-nms/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley